Loss-making Lotte Chemical to sell water treatment unit to Synopex
Lotte Chemical Corp., South Korea’s second-largest petrochemical company grappling with mounting losses amid a prolonged industry downturn, wi...
Mirae Asset debuts AI-recommended ETF on NYSE to invest in US bonds
Mirae Asset Financial Group, one of the largest asset managers in South Korea, has launched its first exchange-traded fund (ETF) investing in high-q...
South Korea’s Rznomics inks $1.3 bn out-licensing deal with Eli Lilly
Rznomics Inc., a South Korean RNA therapeutics developer, has signed an agreement worth more than $1.3 billion with US pharmaceutical giant Eli Lill...
South Korea to boost aid for chipmakers to $23 billion, expanding extra budget
South Korea’s government is planning to increase support for chip makers to around $23 billion, proposing a bigger-than-expected supplementary...
Celltrion wins EU approval for autoimmune disease treatment Avtozma
Celltrion Inc.’s Avtozma, a biosimilar to Roche’s autoimmune disease treatment Actemra, has won approval from the European Commission, f...
SK Ecoplant seeks to sell waste treatment business for $1.4 billion
SK Ecoplant Co., a South Korean construction engineering and waste management company under SK Group, is seeking to dispose of its waste treatment b...
LG Chem embarks on sale of dermal filler business worth $343 million
LG Chem Ltd., the world’s fourth-largest chemicals producer that is fostering vaccine and new drug development as new growth drivers, has kick...
Celltrion’s Vegzelma: Most-prescribed cancer treatment in Europe
South Korea’s leading biosimilar drug developer Celltrion Inc.'s Vegzelma, a cancer drug referencing global biopharma Roche’s Avastin, h...
Yuhan’s lung cancer drug gets OK in Europe
Leclaza (ingredient: lazertinib), a new lung cancer treatment developed by South Korea’s Yuhan Corp. secured approval from the European Commis...
Celltrion obtains approval of Steqeyma from FDA
South Korea's Celltrion Inc. said on Wednesday it received new drug submission (NDS) approval from the Food and Drug Administration (FDA) for Steq...
SK Pharmteco bags obesity treatment deal worth up to $1.4 bn
SK Pharmteco Co., a contract development and manufacturing organization (CDMO), has secured an obesity treatment order worth up to 2 trillion won ($...
Celltrion gets approval of Omlyclo in Canada
South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Omlyclo, the biosimilar of allergic asthma an...
Celltrion releases Steqeyma in Europe
South Korea's Celltrion Inc. said on Monday it released Steqeyma (ustekinumab) in Europe, the biosimilar of autoimmune disease treatment Stelara.T...
DS Dansuk wins $750 mn SAF material order from Phillips 66
South Korea's DS Dansuk Co., which operates bioenergy, battery, and plastic recycling businesses, said on Monday it signed a 1 trillion won ($750 mi...
ViGenCell obtains approval for HLA-B5801 genetic diagnostic kit for adverse reactions to gout treatment
ViGenCell, a company specializing in immunotherapy, announced on Friday that it has obtained approval from the Ministry of Food and Drug Safety (MFD...
Celltrion's anti cancer drugs hold 90% market share in C.America
South Korea’s Celltrion Inc. said on Friday that its cancer treatments have captured a 90% market share in several Central American countries....
Osstem Implant to boost digital dentistry business
South Korea's Osstem Implant Co., the world’s fourth-largest dental implant maker, will enhance its software system of digital dentistry. ...
Celltrion to supply breast, stomach cancer treatment to Brazil
Celltrion Inc., South Korea’s largest biosimilar maker, announced on Friday that its breast and stomach cancer treatment "Herzuma" (active ing...
SK Group’s 3rd-generation daughter comes to the fore
Chey Yoon-chung, the eldest daughter of SK Group Chairman Chey Tae-won, unexpectedly made her debut during an SK Biopharmaceuticals Co. video confer...
GS E&C in talks to sell entire stake in GS Elevator to Chinese firm
South Korea’s GS Engineering & Construction Corp. (GS E&C) is in talks to sell its entire stake in GS Elevator Co. to a Chinese strate...
Celltrion gets approval of Steqeyma in Canada
South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Steqeyma, a biosimilar of the autoimmune dise...
GC Biopharma sells HK subsidiary to CR Pharm Group for $254 mn
South Korea’s GC Biopharma Corp. announced on Wednesday that it signed a share purchase agreement (SPA) to sell all its shares in its Hong Kon...
LG Chem promises extra $14.4 million in aid over Indian gas leak
South Korea’s top chemicals maker LG Chem Ltd. said on Wednesday it will offer an additional 1.2 billion Indian rupees ($14.4 million) in huma...
LG Chem launches Synovian in China
South Korea's LG Chem Ltd. announced on Wednesday that it launched its homegrown new drug for osteoarthritis Synovian (marketed in China as Hyruan O...
Yellow Umbrella's new CIO to spur alternative investment
The Yellow Umbrella Mutual Aid Fund, a 25.4 trillion won ($18.5 billion) savings arm of South Korean small business owners, has tapped an alternativ...
SK Telecom launches AI pet diagnostic solution in Australia
South Korea's SK Telecom Co. announced on Wednesday that it launched its AI-based pet diagnostic assistance service X Caliber in Australia and has b...
Handok gets Biocon's obesity drug exclusive distribution in S.Korea
South Korean pharmaceutical company Handok Inc. announced on Friday that it signed an exclusive domestic sales and distribution agreement with India...
Investors dump Korean biotech HLB stocks on FDA rejection
HLB Co. and its affiliate stocks tumbled on Friday on news that the South Korean biotech group’s highly anticipated new cancer treatment Rivoc...
South Korea Plans $7 Billion Push to Pivot EV Battery Industry Away From China
South Korea is dedicating around $7 billion to help wean its electric-vehicle battery supply chain away from China and align more with U.S. trade gu...
Celltrion to supply Remsima, Herzuma to Peru
South Korea's Celltrion Inc. announced on Thursday that it secured a contract to supply its biosimilars for autoimmune disease treatment and antican...
